drugset
drugset / Trial / NCT02183662

Safety and Pharmacokinetics of Single Rising Oral Doses of BI 224436 ZW in Healthy Male Volunteers.

NCT02183662 ↗

Phase 1 Completed 105 enrolled Boehringer Ingelheim
RandomizedCrossoverDouble-blindTreatment

Summary

To investigate safety and pharmacokinetics of BI 224436 ZW

Timeline

Start
2009-11
Primary completion
2010-03
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 224436 Small molecule 6.2 mg Oral
Subject BI 224436 Small molecule 12.5 mg Oral
Subject BI 224436 Small molecule 25 mg Oral
Subject BI 224436 Small molecule 50 mg Oral
Subject BI 224436 Small molecule 100 mg Oral
Subject BI 224436 Small molecule 200 mg Oral
Subject BI 224436 Small molecule 400 mg Oral
Subject BI 224436 Small molecule 600 mg Oral
Subject BI 224436 Small molecule 900 mg Oral
Subject BI 224436 Small molecule 1200 mg Oral

Indications

No indication recorded.